Deep grey matter volume loss in the brain drives multiple sclerosis (MS) progression and disability, and is particularly evident in people with progressive forms of the disease, a retrospective ... Read more
The Consortium of Multiple Sclerosis Centers has updated guidelines for using magnetic resonance imaging to evaluate people suspected of having multiple sclerosis.
Doctors use the MRI guidelines not only to ... Read more
MSBase and icometrix have joined efforts in a large-scale project to identify imaging markers of multiple sclerosis (MS) that could help diagnose the disease in its early stages.
The combination ... Read more
Multiple sclerosis patients who start Rituxan (rituximab) treatment are three times more likely to have unchanged or improved brain-scan readings than worse ones, according to a study. Holy Name ... Read more
Progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with Tysabri (natalizumab) is linked to better outcomes if the condition does not give rise to actual symptoms and ... Read more
Royal Philips will introduce a new suite of magnetic resonance (MR)-based software applications at the upcoming Radiological Society of North America’s 102nd Scientific Meeting and Annual Assembly (RSNA 2016; #RSNA16) Nov. 27 to Dec. ... Read more
A large study of multiple sclerosis patients (MS) came to the conclusion that clinical and brain imaging assessments drawn from magnetic resonance imaging (MRI) scans are poor measures of long-term prognosis ... Read more
Detecting brain atrophy in multiple sclerosis (MS) patients requires high quality scans, too expensive and complicated for routine clinical use. But this may change with a new software that simplifies ... Read more
Researchers working with magnetic resonance imaging (MRI) are often faced with a problem: an average MRI brain scan produces a considerable amount of images (around 600 megabytes), but half carry distortions ... Read more
Results from the BENEFIT11 trial indicate that early treatment with IFNB-1b leads to improvements in cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging ... Read more
Results from a Phase 3 clinical trial entitled “AVANCE” revealed promising clinical outcomes in patients with relapsing-remitting multiple sclerosis treated for one year with peg interferon beta-1a. The analysis was published in ... Read more